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Abstract
Background: Reported patterns of familial aggregation of head and neck
cancer (HNC) vary greatly, with many studies hampered by the limited
number of subjects.
Methods: Altogether 923 early-onset (≤40 years old) HNC probands, their
first-degree relatives, spouses, and siblings' offspring were ascertained. Cumu-
lative risk and standardized incidence ratios (SIRs) were estimated.
Results: Of all early-onset HNC families, only 21 (2.3%) had familial HNC cancers
at any age and less than five familial early onset HNC cancers among first-degree
relatives. The cumulative risk of HNC for siblings by age 60 (0.52%) was at popula-
tion level (0.33%). No increased familial risk of early-onset HNC could be discerned
in familymembers (SIR 2.68, 95%CI 0.32-9.68 for first-degree relatives).
Conclusions: Our study indicates that the cumulative and relative familial risk of
early-onset HNC is modest in the Finnish population and, at most, only a minor
proportion of early-onset HNCs are due solely to inherited geneticmutations.
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1 | INTRODUCTION
Head and neck cancers (HNC) comprise a heterogeneous
group of malignancies occurring in the lip, oral cavity,
salivary glands, nasal cavity, paranasal sinuses, pharynx,
and larynx. Epidemiologically, HNCs represent the
seventh most common cancer and account approximately
for 5% of all malignancies globally.1 While HNCs cover
only 1% to 4% of all cancers in Western countries,
they constitute one of the most common malignancies
in several developing countries.1-3 Moreover, over the
past three decades, increasing numbers of young
patients (≤40 or ≤45 years old depending on the study)
worldwide have been diagnosed with HNC.4 Tobacco
and alcohol use are the most common reported etiologi-
cal factors, but infection with human papillomaviruses
(HPV), particularly type 16, has also been linked to the
pathogenesis of HNCs arising especially from the oro-
pharynx.5,6 The average latency period for HPV-positive
oropharyngeal cancer has been estimated to be of
approximately 10 to 30 years.7
The term familial cancer is applied to designate a cancer
occurring in families more often than would be expected by
chance.8 In contrast to sporadic cancers, these cancers often
develop at an early age, due to inherited germline muta-
tions, but may also be a sign of early shared environmental
or lifestyle factors that result in genetic aberrations.9 The
concept of familial cancer was first described in breast can-
cer literature by James Paget in England and Paul Broca in
France, as early as in the 1800s.10,11 The degree to which
site-specific cancers run in families has been investigated in
several studies. The overall heritability of cancer has been
reported to be 33% (95% CI 30%-37%) based on a large twin
cohort.12 By discerning familial patterns of cancer inci-
dence, a variety of familial cancers have been defined, most
notably familial breast and colorectal cancers, which are
estimated to account for approximately 10% to 30% and 30%
of all breast and colorectal cancers, respectively.13,14
Although the majority of HNCs are sporadic, that is,
the consequence of somatic mutations, many of which
are related to smoking or alcohol consumption,5 earlier
reports of familial clusters of HNC, also in young individ-
uals, provided the first suggestion that at least a heredi-
tary but rare form of HNC might exist.15-17 The
occurrence of familial clustering of cancer in young fam-
ily members is commonly thought to favor the existence
of predisposing genetic factors.18 Reported patterns of
familial aggregation of HNC vary greatly, with many
studies hampered by the restricted number of subjects
and the comprehensible difficulty to distinguish between
inherited and environmental risk factors.19-21 Moreover,
the incidence of early-onset HNC is low, covering less
than 5% of all HNC cases,4 and few centers have had the
opportunity to address the question of familial cancer
risk in this patient group separately, with conflicting
results.17,22 This dearth of data has resulted in only mini-
mal inroads to elucidate the familial risk of HNC.
Recently, a 43% increased risk of HNC was reported for
relatives of HNC patients (≤60 years old), when com-
pared with family members of healthy controls.23
In this study, our primary goal is to characterize the
familial relative and cumulative risks of HNC and other
malignancies, including cancers of both the digestive and
respiratory organs, for family members and spouses of
patients previously diagnosed with early-onset HNC
(≤40 years old). By investigating familial clustering of
HNC, we aim to assess the etiological impact of genetic
and shared environmental factors on the disease.
2 | PATIENTS AND METHODS
ICD-O-3 topographical codes were used to identify an epide-
miological series of patients diagnosed with primary early-
onset HNC (≤40 years old) in Finland from 1970 to 2012
from the Finnish Cancer Registry (FCR). In this study, HNCs
were defined as malignancies occurring in the lip (ICD-O-3:
C00.0-C00.9), oral cavity (C01.9-C06.9), salivary glands
(C07.9-C08.9), pharynx (C09.0-C14.8), nasal cavity and mid-
dle ear (C30.0, C30.1), paranasal sinuses (C31.0-C31.9), and
larynx and epiglottis (C32.0-C32.9).
The FCR includes all new primary cancers diagnosed
in Finland since 1953 with complete follow-up data until
death or emigration. Quality assessment studies have
shown high coverage (94.8% of HNCs) and accuracy of
diagnosis.24 The Population Information System is a reg-
istry of all permanent Finnish residents and records
information on family linkages, dates of birth and death,
and permits reliable identification of family members
and spouses. Links to siblings are available for individ-
uals born after 1955 and alive in 1967.
We define as proband the first member of a family diag-
nosed with HNC at or under the age of 40 years between
January 1, 1970 and December 31, 2012, in Finland.25 We
define as family member any blood relative. Probands with
no family members or spouses were excluded from the
study. Using the Population Information System, family
members (parents, offspring, siblings, and siblings' off-
spring) and spouses were linked to the probands. The
follow-up for all family members and spouses of the pro-
bands begins either at the date of birth or January 1, 1953
and ends either at the date of the cancer diagnosis, date of
death or emigration, or December 31, 2016. To account for
immortal time bias, family members and spouses of the pro-
bands were not considered to be at risk of cancer between
January 1, 1970 and the date of diagnosis of the proband.
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As a measure of familial aggregation of HNC, we used
standardized incidence ratios (SIRs), which were esti-
mated using all follow-up outside the immortal periods
in order to quantify the risk of cancer in family members
and spouses with a proband diagnosed with early-onset
HNC, relative to general population incidence of HNC in
Finland.26 The SIR estimates the risk of a cancer develop-
ing in a family member or spouse of the proband relative
to the first occurrence of cancer among the general popu-
lation. SIR is thus a ratio of observed cancers to expected
cancers, in which the expected number of cancers was
calculated for the general population. SIRs were esti-
mated for all first-degree relatives (parents, offspring, and
siblings) of the proband combined and for family mem-
bers (first-degree relatives and siblings' offspring) and
spouses distinctly by kinship to the proband, separately
for early-onset (≤40 years) and late-onset (≥41 years)
cancers. SIRs were computed for HNC, digestive organs'
and respiratory organs' cancers. Cumulative risks and
expected cumulative risks from 0 to 60 years of age were
estimated for probands' siblings. In the estimation of
cumulative risks, we considered only follow-up after the
diagnosis date of the proband.
Statistical analyses were performed using the R soft-
ware (The R Project for Statistical Computing) version
3.6.0 with Epi package version 2.38 and popEpi package
version 0.4.7. P-values and confidence intervals for SIRs
were computed using normal approximation for Poisson-
model coefficient. The probands were excluded from the
analyses to account for the ascertainment bias due to
nonrandomly selected families. P-values were two-sided
and unadjusted for multiple testing. For data privacy rea-
sons, we do not report observed values, if less than five
cases were reported. Research permission for the study
design was granted by the National Institute for Health
and Welfare in Finland (Dnro THL/264/5.05.00/2015).
3 | RESULTS
Between the January 1, 1970 and the September
30, 2012, 24 601 occurrences of HNC were registered in
the Finnish Cancer Registry, with a total of 1061 early-
onset HNC patients (approximatively 4% of HNCs were
diagnosed under the age of 40 years), of whom 923 had
at least one family member or spouse. Number of
TABLE 1 Numbers of probands according to HNC site
Site ICD-10 Number Median age % of males
Lip C00.0-C00.9 63 36.6 [32.4-39.0] 85.7
Mouth, other C01.9, C03.0-C06.9 119 33.8 [28.9-38.0] 49.6
Tongue C02.0-C02.9 193 33.2 [29.2-37.6] 58.5
Salivary glands C07.9-C08.9 239 31.7 [26.5-36.8] 45.6
Pharynx C09.0-C14.8 153 34.0 [25.4-38.2] 63.4
Nose, sinuses C30.0-C31.9 88 33.3 [25.9-38.1] 61.4
Larynx, epiglottis C32.0-C32.9 68 37.8 [35.3-39.8] 83.8
Total 923 33.9 [28.0-38.2] 58.8
Note: Median age at diagnosis with interquartile range (IQR) and proportion of males are shown. Probands with no family members or
spouses were excluded.
TABLE 2 Numbers of cancer cases among 923 families consisting of 6714 family members and 1834 spouses at any age
Primary site in family
members and spouses ICD-10
Number of families Familial cancers
Number of cases among family
members and spouses
Total Number of cancers Number of families (%)0 1 2 3 4 >4
Head and neck C00-C32 902 21 0 0 0 0 923 21 21 (2.3%)
Digestive organs C15-C26 800 114 9 0 0 0 923 132 123 (13.3%)
Lung or trachea C33-34 855 66 1 1 0 0 923 71 68 (7.4%)
Any cancer 472 321 101 21 5 3 923 622 451 (48.9%)
Note: The proband was diagnosed with HNC at age 40 years or less. Probands with no family members or spouses were excluded.
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probands included in the study by HNC-subsite are
presented in Table 1. The median age of probands was
33.9 years (interquartile range 28.0-38.2) and 58.8% of
probands were men. The salivary glands and the tongue
were the most common sites of early-onset HNC among
probands, accounting for 25.9% (n = 239) and 20.9%
(n = 193) of all cases, respectively.
Probands' family members consisted of first-degree
relatives (n = 4371, 50.6% of all family members) and sib-
lings' offspring (n = 2433, 28.2%). Altogether probands'
TABLE 3 Observed cancers and standardized incidence ratios (SIRs) with 95% confidence intervals (CI) for family members and
spouses at age ≤ 40 years with a proband diagnosed with early-onset HNC (≤40 years old)
Primary site in family members and spouses at age ≤ 40 Number Observed Expected PYR SIR [95% CI] P-value
Head and neck
First degree relatives 4281 <5 <5 78 027 2.68 [0.32-9.68] .383
Siblings' offspring 2433 <5 <5 48 943 3.00 [0.08-16.7] .772
Spouse 1834 0 0.31 33 077 0.00 [0.00-11.9] .731
Digestive organs
First degree relatives 4281 <5 <5 78 079 0.78 [0.09-2.80] .96
Siblings' offspring 2433 <5 <5 48 931 1.70 [0.21-6.13] .767
Spouse 1834 <5 <5 33 073 1.68 [0.20-6.07] .776
Lung or trachea
First degree relatives 4281 <5 <5 77 996 2.31 [0.06-12.9] .919
Siblings' offspring 2433 0 0.12 48 948 0.00 [0.00-29.9] .284
Spouse 1834 0 0.2 33 077 0.00 [0.00-18.7] .496
Any cancer
First degree relatives 4281 25 28.2 78 510 0.89 [0.57-1.31] .609
Siblings' offspring 2433 20 16.4 48 765 1.22 [0.75-1.89] .441
Spouse 1834 9 13.7 33 056 0.66 [0.30-1.25] .255
TABLE 4 Observed cancers and standardized incidence ratios (SIRs) with 95% confidence intervals (CI) for family members and
spouses at any age with a proband diagnosed with early-onset HNC (≤40 years old)
Primary site in family members and spouses at
any age Number Observed Expected PYR SIR [95% CI] P-value
Head and neck
First degree relatives 4371 19 15.2 144 595 1.25 [0.75-1.95] .398
Siblings' offspring 2433 <5 <5 49 964 2.46 [0.06-13.7] .883
Spouse 1834 <5 <5 60 791 0.21 [0.01-1.17] .136
Digestive organs
First degree relatives 4371 104 101 144 489 1.03 [0.84-1.25] .813
Siblings' offspring 2433 <5 <5 49 954 1.38 [0.17-4.98] .967
Spouse 1834 26 26.2 60 659 0.99 [0.65-1.46] .946
Lung or trachea
First degree relatives 4371 55 54.4 144 599 1.01 [0.76-1.32] .984
Siblings' offspring 2433 0 0.19 49 970 0.00 [0.00-19.8] .467
Spouse 1834 16 12 60 775 1.33 [0.76-2.17] .313
Any cancer
First degree relatives 4371 469 472 142 440 0.99 [0.91-1.09] .898
Siblings' offspring 2433 25 18.4 49 759 1.36 [0.88-2.01] .155
Spouse 1834 128 155 60 052 0.83 [0.69-0.98] .035
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family members (n = 6804, 78.8%) and spouses
(n = 1834, 21.2%) contributed 252 251 to 255 350 person-
years (PYR) of follow-up (depending on family members'
or spouses' primary site of cancer). The study comprised
4281 first-degree relatives of age ≤40.
In 21 families (2.28% of all families), two individuals
(proband and one family member or proband and
spouse) were affected by HNC (Table 2). There were no
families with more than two individuals (including pro-
band) affected with HNC. Of the 21 HNCs observed
among family members or spouses of probands, 10 cases
were observed in the pharynx (C01, C09-14) and less than
five cases in each of the other anatomic locations.
Of the family members affected with HNC, less than
five were younger than 40 (less than 0.50% of all families
affected or less than 0.07% of all family members). Simi-
larly, less than five cases of cancer of the digestive organs
and less than five cases of cancer of the respiratory
organs, were diagnosed in family members of age ≤40.
Most of the observed cancer cases in probands' family
members occurred after the age of 40.
Familial relative risks (SIRs) for family members and
spouses are outlined in Table 3 (age ≤ 40) and Table 4 (any
age). No statistically significant elevated familial relative
risk of cancer could be discerned in probands' first-degree
relatives or siblings' offspring, neither at age ≤ 40 nor at
>40. For probands' spouses at any age, the SIRs for HNC
(SIR 0.21, 95% CI 0.01-1.17, P = .136) and for any cancer
(SIR 0.83, 95% CI 0.69-0.98, P = .035) were lower than for
the general population. The SIR for any cancer was also
lower for spouses at age > 40 (SIR 0.84, 95% CI 0.70-1.01,
P = .069), when compared to the general population.
Among the 4371 first-degree relatives, HNC had been
diagnosed in less than 0.10% at age ≤ 40 and in 0.43% at
any age. Correspondingly, digestive and respiratory organ
cancers were diagnosed in 2.38% and 1.26% of the pro-
bands' first-degree relatives at any age, respectively. It
could be observed that the cumulative risk for probands'
siblings by age 60 (0.52%, 95% CI 0.19-1.39) did not mark-
edly differ from the general population's risk (0.33%, 95%
CI 0.32-0.34), as shown in Figure 1. There were no cases
of early-onset HNC (age ≤ 40) among siblings.
4 | DISCUSSION
The majority of HNC cases are sporadic, representing
more than 97% of cases in this familial cohort. No
increased relative risk of HNC or other malignancies
could be discerned in first- or second-degree relatives of a
patient diagnosed with early-onset HNC (≤40 years old),
when compared to the risk in the general population.
Among the first-degree relatives of probands diagnosed
with early-onset HNC, less than 0.10% were diagnosed
with HNC at age ≤ 40 and 0.43% at any age.
This study utilizes a large population-based database
from the Finnish Cancer Registry (FCR), first, to deter-
mine the fraction of HNC cases that can be considered to
exhibit familial clustering, and secondly, to define the rel-
ative risk of HNC for family members and spouses of
patients previously diagnosed with early-onset HNC. This
work highlights the fact that at most, only a trivial pro-
portion of HNCs is primarily and solely due to inherited
genetic mutations. Although a family cancer history can-
not be altered, findings could provide the basis for the
development of improved clinical management of HNC
cancer families and adequate cancer screening guidelines
for this patient population.
Family history of cancer can be used as a proxy to
detect not only genetic predisposition to disease, but also
shared environmental and lifestyle factors that can con-
tribute to multiple cancers in the same family.27 In con-
trast to other studies, focusing on families with early-
onset HNC permits to disentangle potential inherited fac-
tors of HNC, as high-penetrance genetic mutations are
commonly assumed to manifest at an early age.18 More-
over, by including extended family members (probands'
siblings' offspring) and spouses, the data are likely to hold
more statistical power than studies restricted to specific
genetic relationships, such as those focusing on twins or
FIGURE 1 Cumulative risk of head and neck cancer (HNC)
in probands' siblings. Five siblings were diagnosed with HNC
during follow-up [Color figure can be viewed at
wileyonlinelibrary.com]
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parents. The strength of our study also lies in the accu-
racy of cancer information contained in the FCR and the
information on probands' family members and spouses.
Risk of HNC in family members and spouses was esti-
mated with SIRs, which mitigates the confounding effects
of ascertainment and immortal biases, and the used
Poisson excess risk model adjusts not only for censoring
in time-to-event outcomes, but also for alterations in pop-
ulation cancer risk by calendar time, age and sex.
Several case-control studies in different countries
have reported an elevated risk of HNC in subjects with a
family history of HNC. Foulkes et al reported in two
independent studies an adjusted relative risk of 3.79 (95%
CI 1.11-13.0) and 3.65 (95% CI 1.97-6.76) in Canada and
Brazil, respectively. The adjusted relative risk for HNC
was 7.89 (95% 1.50-41.6) in first-degree relatives of
patients with multiple primary head and neck
tumors.16,28 Risks in these two studies were adjusted for
age, sex, city, and tobacco and alcohol consumption. In
the study of Garavello et al, conducted in Switzerland
and Italy, the odds ratios (OR) were 3.1 (95% CI 2.0-4.8)
for oropharyngeal and laryngeal cancers combined and
7.1 (95% CI 1.3-37.2) for subjects with two or more first-
degree relatives affected.29 A French study similarly
described an elevated risk for HNC among first-degree
relatives of HNC probands (OR = 1.9, 95% CI 1.2-2.8),
which increased with the number of first-degree relatives
affected.30 A pooled international study, comprising
12 case-control studies (8967 patients and 13 627 con-
trols), also established that a family history of HNC in
first-degree relatives increased the risk of HNC (OR 1.7,
95% CI 1.2-2.3). Noteworthy, this risk was limited to sub-
jects with a history of tobacco smoking or alcohol con-
sumption.31 A second pooled international study,
consisting of 25 case-control studies, concluded that
young adults (≤45 years old) with a family history of
early-onset HNC had an increased risk of HNC (OR 2.27,
95% CI 1.26-4.10), which was not detectable in their older
counterparts. Risk estimates were adjusted for sex, race,
age, education level, and tobacco and alcohol consump-
tion.22 In compliance with the previous findings, a study
conducted in Utah (USA), by means of population-based
genealogy and state cancer registry databases, reported a
relative risk for first-degree relatives of 5.31 (95% CI
1.45-13.59, P = .0074). For second-degree relatives, no
statistically significant elevated risk could be noted.21
Renkonen et al, in a comparably designed study con-
ducted in Sweden, established a 1.43-fold increased risk
(95% CI 1.28-1.61) for developing HNC in first-degree rel-
atives of HNC patients when compared to relatives of
healthy controls.23 Risk estimates were, however, not
adjusted for confounding factors, such as tobacco and
alcohol consumption, in these two studies.
In contrast to the previously quoted studies, Copper
et al., in a case-control study (not adjusted for risk fac-
tors), conducted in the Netherlands and including
105 cases with 617 first-degree relatives, found no higher
rate of HNC in probands' first-degree relatives.32 Gold-
stein et al in a similar study consisting of 487 cases and
485 controls and adjusted for tobacco and alcohol con-
sumption, concluded that there is, at most, a weak famil-
ial aggregation of oropharyngeal cancers.19 Huang et al
did not observe a strong association between family his-
tory of HNC and HNC risk after taking into account life-
style factors (tobacco smoking, alcohol consumption, and
betel quid chewing) in a Chinese population comprising
921 cases.20 When focusing on early-onset HNC, our
results are in line with Mork et al who reported no
increased risk of HNC or esophagus and lung cancers for
first-degree relatives of patients diagnosed with HNC at
age ≤45. The study comprised, however, only 127 HNC
probands and risk estimates were not adjusted for risk
factors.17
Interestingly, spouses of probands in our study had a
lower relative risk of HNC and other malignancies
(SIR = 0.83, 95% CI 0.69-0.98, P = .035). The results are
in contrast to the study of Renkonen et al, that reported
an increased risk for spouses of HNC probands (hazard
ratio of 1.25, 95% CI 1.01-1.53).23 Other studies have simi-
larly reported an increased risk. In the study of
Hemminki et al, stomach, lung, and bladder, showed
concordant increases of cancer among spouses (mini-
mum 15 years of cohabitation on average) with SIRs
ranging from 1.19 to 1.38.33 Likewise, a modest trend of
increased risk in HPV-associated cancers among spouses
of patients with HPV-related cancer has been described.34
The reduced risk in our study could be attributed to low-
risk lifestyle behaviors adopted by spouses after diagnosis
of the proband's cancer, or it may simply be an artifact
due to confounding variables, such as smoking habits
and HPV-status, not adjusted for. Also, the definition of
spouse in our study did not include any specific time
period, which entails the possibility of underestimating
the risk.34
While the existing literature reveals an increased can-
cer risk among subjects with a family history of HNC, the
amplitude of the risk varies across studies. A few factors
relating to the aforementioned studies need to be consid-
ered. Certain case-control studies obviously present a lim-
itation of power, as the number of cases was limited.
More importantly, methodological difficulties that may
bias risk estimations among the different studied
populations must be considered. In most of the cited
studies, cases of cancer among probands' relatives were
not confirmed but were self-reported by the probands
themselves by means of questionnaires or interviews,
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which could lead to reporting bias. It has been indeed
demonstrated that people have a tendency to over-report
their medical and cancer screening history, so an over-
reporting history of family cancer cannot be completely
ruled out.35,36 However, underreporting for certain can-
cers has also been described.37 The studies by Monroe
et al and Renkonen et al were the only ones based on
cancer registries and genealogy databases, but, as already
stated before, did not adjust for confounding factors. It is
nevertheless likely that the genetic risk profiles vary
across populations, as has been detected for some alterna-
tive phenotypes associated with DNA repair enzymes or
the metabolism of carcinogens, which could, at least par-
tially, explain the disparities between the different
populations.38-41 Several phenotypes involved in carcino-
gen metabolism have been linked to HNC risk, though
results have not always been in agreement.42-44 As a con-
sequence, extrapolations of results of individual studies
to other populations cannot be made without further
evaluation.
Familial clustering of cancer may hint to inheritable
genetic factors, but may also suggest similar environmen-
tal or behavioral risk factors, such as alcohol and tobacco
consumption, among family members and spouses.
Tobacco use by family members has been reported to
increase the risk of tobacco use in an individual and may
partially explain the higher rates of tobacco-associated
malignancies in subjects with a family history of oropha-
ryngeal cancer.45,46 Also, the involvement of dietary risk
factors, such as consumption of nitrosamine-rich salted
fish, as observed in Southeast Asia reporting one of the
highest incidences of nasopharyngeal cancer, can explain
familial clustering of HNC in certain families.47 In
regards to the pattern of alcohol use, studies have linked
genetic mutations in alcohol metabolism genes to an
increased risk of HNC.44 Consequently, it is not uncon-
ceivable that the familial risk of HNC results not only
from lifestyle factors but from inherited faulty genes
along with cumulative carcinogenic exposures, that is,
somatic and germline mutations. The interactions
between genetic susceptibility and continuous environ-
mental factors, as smoking, alcohol consumption, infec-
tion with HPV, and dietary exposure, may have critical
implications in carcinogenesis. HNC would be assumed
to develop in these circumstances at a later age, which
may then explain why the risk of HNC was not elevated
when focusing on early-onset HNC, in contrast to other
studies with no age cutoff or with a cutoff at a later age
than in our study. However, only a few of these
genotype-environment interactions have been docu-
mented, due comprehensibly to the intricate nature of
this complex polygenic interplay.48,49 Based on the results
of a meta-analysis, a polymorphism (Arg194Trp)
associated with the DNA repair gene XRCC1 was
described as having an effect on HNC risk in smokers,
even though the involvement was suggested to be
minor.50 Another study concluded that specific polymor-
phisms of the anti-apoptotic protein survivin, combined
with betel quid chewing and/or tobacco consumption,
could substantially promote predisposition to oral can-
cer.51 Some evidence of increased HNC risk also exists
for certain genotypes associated with the genes ADH1B,
coding the enzyme alcohol dehydrogenase 1B involved
in ethanol catabolism, and HEL308, coding the enzyme
helicase involved in polymerase pathway when associ-
ated with tobacco consumption.52 These findings hint
that a familial factor in the pathogenesis of HNC could
be attributable to inherited germline mutations
predisposing to sensitivity toward tobacco- and alcohol-
related carcinogens.
Some inherent weaknesses in our study should be
acknowledged. The inability to evaluate the effects of
HPV status and smoking or alcohol consumption habits
sets restrictions on speculating any underlying mecha-
nisms, especially those supporting interactions between
inherited susceptibility and environmental risk factors.
Neither was any information available on genetic varia-
tions of potential susceptibility genes. The environmental
risk factors represent genetic modifying factors that inter-
fere with the ability to elucidate the precise genetic
involvement in disease-onset, and our risk estimates
could not be adjusted for these factors. Other caveats
relate to the short follow-up for late-onset cancers in pro-
bands' family members and spouses, which results in less
statistical power, especially for late-onset effects. Also, a
lower fertility rate among early-onset cancer subjects
may lead to observing more cancer-free relatives and thus
to an underestimation of the cancer risk in these fami-
lies.53 Early-onset HNC is associated with moderate sur-
vival (73% survival rate after eight years of follow-up in
15-39 year-old patients) and mortality of early-onset can-
cer probands before reproduction could also predispose
to an underestimation of the familial risk in our study.54
The cumulative incidence for HNC for first-degree
relatives of a proband diagnosed with early-onset HNC
was less than 0.10% by age 40. Evidence linking shared
genetic mutations with some early-onset cancers
exists.55,56 However, our study indicates that the contri-
bution of shared familial factors, such as inherited
germline components or early HPV-exposure, to early-
onset HNC is, at least in the Finnish population, negligi-
ble from a clinical point of view and, at most, only a
minor proportion of HNCs are due solely to inherited
genetic mutations. Instead, environmental factors, such
as tobacco and alcohol consumption, yielding somatic
mutations or genotype-environment interactions, may
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play a more prominent role in disease onset. In order to
disentangle the precise contribution of genetic and envi-
ronmental components to familial HNC risk, larger study
populations and longer follow-up periods are warranted.
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